Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

Why It Matters

The results demonstrate that Senseonics’ long‑term CGM is gaining commercial traction, positioning the firm for accelerated market share and profitability as it scales globally.

Key Takeaways

• Q4 revenue $14.3M, 72% YoY increase.
• Full‑year revenue $35.3M, 57% YoY growth.
• CE Mark secured for Eversense 365 in EU.
• Gemini sensor pivotal trial IDE approved, first patient enrolled.
• 2026 revenue forecast $58‑62M, 65‑76% growth.

Pulse Analysis

Senseonics’ latest earnings underscore a pivotal shift from early‑stage development to commercial scalability. Aggressive direct‑to‑consumer campaigns and an expanded inserter network drove a 103% surge in new U.S. patients, while active prescribers jumped over 80%. These sales‑force enhancements, coupled with higher gross margins on the year‑long Eversense 365 sensor, lifted Q4 revenue to $14.3 million and pushed full‑year sales past $35 million, marking the strongest top‑line performance in the company’s history.

Regulatory milestones further reinforce the growth narrative. The CE Mark approval unlocks the European market for the year‑long CGM, a segment still dominated by short‑term wearables. Simultaneously, the FDA granted an IDE for the self‑powered Gemini sensor, with the first patient already enrolled, signaling a next‑generation product pipeline. The launch of the twiist Automated Insulin Delivery system integration expands the ecosystem, offering clinicians a seamless CGM‑to‑insulin workflow. Additionally, the transition of commercialization duties back from Ascensia to Senseonics in 2026 promises tighter margin control and direct market feedback.

Looking ahead, the company’s 2026 outlook projects $58‑62 million in revenue, a 65‑76% increase, driven by European roll‑out, broader AID compatibility, and continued DTC investment. With $94 million in cash and manageable debt, Senseonics is well‑positioned to fund its expansion and R&D initiatives. If the Gemini trial confirms performance, the firm could capture a larger share of the growing implantable CGM market, challenging competitors reliant on shorter wear periods and potentially delivering sustained profitability for investors.